Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS-4: Elinzanetant for Vasomotor Symptoms in HR+ Breast Cancer
NCT05587296Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Oct 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in vasomotor symptoms comparing Elinzanetant with Placebo -> Elinzanetant (2 arms). Primary endpoint: Mean Change in Frequency of Moderate to Severe Hot Flashes at 4 weeks. Started Oct 2022; status: active, not recruiting.
02
Drugs
elinzanetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT05587296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05587296.